Method for Reconstructing Liposomal Anamycin
A method for reconstituting liposomal anamycin using temperature-controlled saline dilution stabilizes the formulation, addressing formulation challenges and ensuring high purity and effective cancer treatment.
Patent Information
- Application Number
- KR1020227000486
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-28
- Filing Date
- 2020-06-25
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2040-06-25
AI Technical Summary
Anamycin, a cancer chemotherapy agent, presents formulation challenges due to its inherent physical properties and instability, leading to inconsistent purity and quality, which can result in degradation and unwanted side effects, and existing methods fail to provide consistent drug formulations that meet regulatory standards.
A method for reconstituting liposomal anamycin involves preheating physiological saline to specific temperatures, maintaining containers within a range, and carefully diluting and storing the formulation to achieve consistent concentrations and stability, ensuring high purity and effective dosing.
The method ensures the production of stable and pure liposomal anamycin formulations, maintaining consistency and avoiding degradation, thereby providing effective cancer treatment with reduced side effects.
Smart Images

Figure R1020227000486_ABST
Abstract
Description
Technology Field
[0001] This application claims priority to U.S. Provisional Application No. 62 / 868,190 filed on June 28, 2019, the disclosure of which is incorporated herein by reference as if in its entirety. Background Technology
[0002] Anamycin is a cancer chemotherapy agent of the anthracene structural family. Due to its physical and pharmacological properties, compositions of anamycin for doserotypes in which the drug is formulated as liposomes have been described (see US 7,238,366). Clinical trials regarding liposomal anamycin have been described in adult patients with relapsed refractory acute lymphoblastic leukemia (M. Wetzler, et al., Clinical Lymphoma, Myeloma and Leukemia, 13 (4), 430-434 August 2013) and in the treatment of doxorubicin-resistant breast cancer (DJ Booser et al., Cancer Chemother. Pharmacol. 50; 6-8, 2002).
[0003] In drug delivery systems, it is desirable to be able to produce drug formulations of consistent purity and quality to ensure accurate dosing, thereby providing the most effective treatment, while avoiding unwanted side effects caused by impurities. Furthermore, poorly maintained or improperly formulated drug substances can degrade before administration, rendering them ineffective and resulting in the waste of expensive active pharmaceutical ingredients. Regulatory standards also require that consistent levels of drug purity and quantity be provided in accordance with the procedures specified on the label.
[0004] Anamycin presents particularly difficult formulation challenges due to its inherent physical properties and the inherent instability of both the parent drug and the liposomal formulation under specific conditions. Therefore, it would be advantageous to find a consistent method for manufacturing dosed forms of liposomal anamycin that ensure purity and avoid degradation.
[0005] A method is provided to form a liposomal anamycin suspension by reconstituting a free liposomal anamycin lyophilized product.
[0006] A method for reconstitution of anamycin is also provided, comprising the following steps:
[0007] A step of adding preheated physiological saline to one or more containers of pre-liposomal anamycin lyophilized material to form suspended liposomal anamycin with a concentration of about 0.5-1.5 mg / mL;
[0008] A step of maintaining one or more of the above containers at 24-45 ℃;
[0009] A step of diluting the above-mentioned suspended liposomal anamycin with preheated physiological saline to provide liposomal anamycin at a concentration of about 0.5-1.5 mg / mL in physiological saline;
[0010] and
[0011] One or more containers of suspended liposomal anamycin and a step of maintaining the diluted liposomal anamycin at 24-45°C during and after dilution.
[0012] A method for preparing an effective dose of a reconstituted liposomal formulation of anamycin is also provided, comprising the following steps:
[0013] As a step of heating a syringe and a non-PVC IV bag, each containing physiological saline (approx.) 0.9% aqueous injection USP sodium chloride, in an oven or bag warmer at 37°C ± 4°C for at least about 3 hours, wherein
[0014] The volume of physiological saline in the syringe (in mL) is equivalent to the weight (in mg) of the pre-liposomal lyophilized anamycin to be reconstituted, and
[0015] The volume of physiological saline in the above IV bag is equivalent to the total amount of physiological saline in all syringes, and
[0016] A step in which the volume of the above IV bag has a sufficient capacity to contain the total volume of physiological saline and liposomal anamycin for diluting the total dose of liposomal anamycin;
[0017] A step of removing a sufficient number of pre-liposomal anamycin lyophilized vials from a freezer to provide the desired total dose of anamycin, and leaving the vials at room temperature for 30 minutes to 2 hours;
[0018] A step of vigorously shaking each vial of pre-liposomal lyophilized anamycin to break down any dry cake;
[0019] A step of injecting air into each vial from an air-filled syringe until the pressure inside each vial becomes equal;
[0020] A step of adding a fixed volume of 37 ℃ ± 4 ℃ physiological saline from a syringe maintained at 37 ℃ ± 4 ℃ in an oven to a vial containing pre-liposomal lyophilized anamycin in a weight-equivalent vial so that the final anamycin concentration becomes approximately 1 mg / mL, and maintaining negative pressure throughout the addition of the physiological saline;
[0021] Immediately shaking the vial vigorously by hand back and forth for 15 seconds, and then placing the vial inside a resealable polyethylene storage bag;
[0022] A step of repeating the steps of adding physiological saline, shaking the vial, and placing the vial in a storage bag until all vials required for the total dose of anamycin are similarly prepared;
[0023] Step of shaking all vials, 2-4 at a time, for 1-2 minutes, and then a second time;
[0024] A step of storing all vials of reconstituted liposomal anamycin at 37 ℃ ± 4 ℃ for 30 minutes to 1 hour until ready for dilution;
[0025] A step of removing no more than two vials of reconstituted liposomal anamycin at a time from storage at 37 ℃ ± 4 ℃, carefully inverting each vial once, recovering a bubble-free suspension from the vials while maintaining negative pressure throughout the recovery of the suspension;
[0026] A step of slowly introducing the recovered, foam-free suspension of the reconstituted liposomal anamycin into a pre-warmed non-PVC IV bag of physiological saline prepared as above, and repeating this process for a second vial;
[0027] The step of removing the vial, recovering the suspension, and introducing the suspension into a preheated IV bag is repeated until all vials of reconstituted liposomal anamycin required for the total dose of anamycin are introduced into a non-PVC IV bag, thereby providing an IV bag containing a final reconstituted liposomal anamycin at a concentration of about 0.5 mg / mL; and
[0028] A step of stirring the physiological saline and reconstituted liposomal anamycin in the IV bag by carefully inverting the container several times without generating foam.
[0029] A method for treating cancer is also provided, comprising administering an effective dose of diluted liposomal anamycin prepared by the following to a patient requiring it.
[0030] A step of adding preheated physiological saline to one or more containers of pre-liposomal anamycin freeze-dried products to form a liposomal anamycin suspension with a concentration of about 0.5-1.5 mg / mL;
[0031] A step of maintaining one or more of the above containers at 24-45 ℃;
[0032] A step of diluting the above-mentioned suspended liposomal anamycin with preheated physiological saline to provide liposomal anamycin at a concentration of about 0.3 - 0.7 mg / mL in physiological saline; and
[0033] One or more containers of suspended liposomal anamycin and a step of maintaining the diluted liposomal anamycin at 24-45°C during and after dilution.
[0034] The use of diluted reconstituted liposomal anamycin prepared according to the above method is also provided in the manufacture of a drug for cancer treatment.
[0035] Diluted reconstituted liposomal anamycin prepared according to the above method for use in cancer treatment is also provided. Brief explanation of the drawing
[0036] do 1 . A schematic representation illustrating a method for reconstructing liposomal anamycin from a lyophilized liposomal anamycin. do 2 . Histogram result overlay for samples at 20 - 25℃. do 3 . Histogram result overlay for samples at 28 - 42℃. do 4 . Histogram result overlay for samples at 20 - 42℃. Specific details for implementing the invention
[0037] details
[0038] A method for manufacturing a formulation of liposomal anamycin with improved stability and high purity is provided.
[0039] definition
[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which the invention(s) pertain.
[0041] The following terms used in this document have the meanings defined below.
[0042] The term "anamycin" refers to the compound (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracen-5,12-dione having the following structure:
[0043]
[0044] The terms "liposome," "of liposomes," etc., generally refer to spherical structures including lipids, fatty acids, lipid bilayer type structures, monolamellar vesicles, and amorphous lipid vesicles. Typically, a liposome is a completely closed lipid bilayer membrane containing a trapped aqueous volume. Liposomes include atypical forms in which anamycin is located inside the bilayer, is part of the bilayer, and can be adsorbed onto the bilayer. Liposomes can be monolamellar vesicles (possessing a single bilayer membrane) or polylamellar vesicles (an onion-like structure characterized by multiple membrane bilayers, each separated from the next by an aqueous layer). The bilayer consists of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. The structure of the membrane bilayer is such that the hydrophobic (non-polar) "tail" of the lipid monolayer is oriented toward the center of the bilayer, while the hydrophilic "head" is oriented toward the aqueous phase.
[0045] The terms “pre-liposome-freeze-dried” and “pre-liposome freeze-dried” will refer to a non-aqueous material that forms liposomes upon addition to an aqueous solution. In some embodiments, the non-aqueous material is a dry (as in non-liquid, non-gel) material. The term freeze-dried is used expansively and includes dry residues of sublimation of frozen liquids from non-volatile materials, residues of rotary evaporation and similar procedures, and dry compositions that result in liposomes upon addition to an aqueous phase (with or without stirring). It will be particularly understood that “pre-liposome-freeze-dried” is not a liposome form after freeze-drying.
[0046] The term "pre-liposomal anamycin lyophilized" is a pre-liposomal lyophilized in which the drug is anamycin. In some embodiments, the lyophilized is prepared according to the procedure set forth in U.S. Patent Publication 2005 / 0238707, which is incorporated herein by reference for all purposes.
[0047] The term "preheated" means that an article, solution, or suspension is heated to a temperature of about 24-45°C, e.g. 30-45°C, e.g. 37°C ± 4°C, or 37°C ± 2°C, 37°C ± 1°C.
[0048] The term "high-purity anamycin-free liposomal lyophilized product" means that the purity of the material is 95% or higher anamycin when analyzed by HPLC using a verified standard sample. In some embodiments, the anamycin is at least 96% pure, or at least 97% pure, or at least 98% pure, or at least 99% pure.
[0049] In the above section, numerous abbreviations and acronyms have been used, and their full descriptions are provided below:
[0050] DMPC Dimyristoyl Phosphatidylcholine
[0051] DMPG 1,2-dimyristoyl-sn-glycero-3-[phospho-(1'-rac-glycerol) (sodium salt)
[0052] DMSO dimethyl sulfoxide
[0053] IV intravenously
[0054] DEHP bis(2-ethylhexyl)phthalate
[0055] PLA-free liposomal freeze-dried anamycin
[0056] PVC Polyvinyl Chloride
[0057] WFI Water for Injection; in accordance with USP
[0058] Throughout this specification and in the following claims, unless the context requires otherwise, the word “comprising,” or variations such as “comprising” or “comprising,” will be understood to mean the inclusion of the mentioned integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. By citing such specified ranges, it is intended herein that the cited ranges also include all those specific integer quantities between the cited ranges. For example, the range of about 24-45°C is intended to also include 24, 30, 33, 34, 35, 36, 37, 38, 39, 40, and 45°C.
[0059] The full disclosure of each U.S. patent and international patent application mentioned in this patent specification is incorporated herein by reference for all purposes.
[0060] A method for producing liposomal anamycin having excellent uniformity and stability is also provided. A novel method for producing liposomal anamycin having excellent uniformity and stability is provided. In particular, as a method for reconstituting anamycin, a method comprising the following steps is provided:
[0061] A step of adding preheated physiological saline to one or more containers of pre-liposomal anamycin freeze-dried to form suspended liposomal anamycin with a concentration of about 0.5 - 1.5 mg / mL;
[0062] A step of maintaining one or more of the above containers at 24-45 ℃;
[0063] A step of diluting the above-mentioned suspended liposomal anamycin with preheated physiological saline to provide liposomal anamycin at a concentration of about 0.5 - 1.5 mg / mL in physiological saline; and
[0064] One or more containers of suspended liposomal anamycin and a step of maintaining the diluted liposomal anamycin at 24-45°C during and after dilution.
[0065] In some embodiments, the liposomal anamycin suspension has a concentration of 0.5 to 1.5 mg / mL. In some embodiments, the liposomal anamycin suspension has a concentration of 0.8 to 1.2 mg / mL. In some embodiments, the liposomal anamycin suspension has a concentration of about 1 mg / mL.
[0066] In some embodiments, the total weight of anamycin in the diluted suspension added into a preheated physiological saline-containing IV bag is equivalent to the required effective dose.
[0067] In some embodiments, the suspended liposomal anamycin is diluted by adding it into a preheated saline-containing IV bag. In some embodiments, the saline-containing IV bag is at a temperature of 30–45°C. In some embodiments, the saline-containing IV bag is at a temperature of 37°C ± 4°C.
[0068] In some embodiments, the reconstituted liposomal anamycin is formed at 24°C or higher. In some embodiments, the reconstituted liposomal anamycin is maintained at 24°C or higher before and during dilution, and before and during injection. Surprisingly, it was found that the liposomal anamycin is unstable at temperatures below 24°C.
[0069] In some embodiments, the reconstituted liposomal anamycin is maintained at a temperature of 30–45°C. In some embodiments, the reconstituted liposomal anamycin is maintained at a temperature of 30–42°C. In some embodiments, the reconstituted liposomal anamycin is maintained at a temperature of 37°C ± 4°C. In some embodiments, the suspension of liposomal anamycin is maintained at 37°C or near thereto, and the diluted liposomal anamycin is maintained at 37°C or near thereto.
[0070] In some embodiments, the diluted liposomal anamycin has a concentration of about 0.5 mg / mL.
[0071] In some embodiments, a protective sleeve is used over an IV drip line to ensure that diluted liposomal anamycin is delivered at a temperature of 37 °C ± 4 °C or higher. In some embodiments, the sleeve is heated. In some embodiments, the sleeve is insulated.
[0072] In some embodiments, the method for reconstituting anamycin includes the following steps:
[0073] A step of adding physiological saline at 37 ℃ ± 4 ℃ to one or more containers of lyophilized liposomal anamycin to form suspended liposomal anamycin with a concentration of about 1 mg / mL;
[0074] A step of maintaining one or more of the above containers at 37 ℃ ± 4 ℃;
[0075] A step of diluting the above-mentioned suspended liposomal anamycin with physiological saline at 37 ℃ ± 4 ℃ to provide liposomal anamycin at a concentration of about 0.5 mg / mL in physiological saline; and
[0076] One or more containers of suspended liposomal anamycin and a step of maintaining the diluted liposomal anamycin at 37 ℃ ± 4 ℃ during and after dilution.
[0077] In some embodiments, diluted liposomal anamycin is maintained at 37 ℃ ± 4 ℃ before and during administration.
[0078] In some embodiments, the container for lyophilized anamycin is a vial having at least 4 mL of headspace that allows sufficient mixing to form liposomes after the addition of preheated physiological saline. In some embodiments, the vial is 50 mL in size.
[0079] In some embodiments, a method for preparing an effective dose of a reconstituted liposomal formulation of anamycin comprises the following steps:
[0080] As a step of heating a syringe and a non-PVC IV bag, each containing physiological saline (approx.) 0.9% aqueous injection USP sodium chloride, in an oven or bag warmer at 37°C ± 4°C for at least about 3 hours, wherein
[0081] The volume of physiological saline in the syringe (in mL) is equivalent to the weight (in mg) of the pre-liposomal lyophilized anamycin to be reconstituted, and
[0082] The volume of physiological saline in the above IV bag is equivalent to the total amount of physiological saline in all syringes, and
[0083] A step in which the volume of the above IV bag has a sufficient capacity to contain the total volume of physiological saline and liposomal anamycin for diluting the total dose of liposomal anamycin;
[0084] A step of removing a sufficient number of pre-liposomal anamycin lyophilized vials from a freezer to provide the desired total dose of anamycin, and leaving the vials at room temperature for 30 minutes to 2 hours;
[0085] A step of vigorously shaking each vial of pre-liposomal lyophilized anamycin to break down any dry cake;
[0086] A step of injecting air into each vial from an air-filled syringe until the pressure inside each vial becomes equal;
[0087] A step of adding a fixed volume of 37 ℃ ± 4 ℃ physiological saline from a syringe maintained at 37 ℃ ± 4 ℃ in an oven to a vial containing pre-liposomal lyophilized anamycin in a weight-equivalent vial so that the final anamycin concentration becomes approximately 1 mg / mL, and maintaining negative pressure throughout the addition of the physiological saline;
[0088] Immediately shaking the vial vigorously by hand back and forth for 15 seconds, and then placing the vial inside a resealable polyethylene storage bag;
[0089] A step of repeating the steps of adding physiological saline, shaking the vial, and placing the vial in a storage bag until all vials required for the total dose of anamycin are similarly prepared;
[0090] Step of shaking all vials, 2-4 at a time, for 1-2 minutes, and then a second time;
[0091] A step of storing all vials of reconstituted liposomal anamycin at 37 ℃ ± 4 ℃ for 30 minutes to 1 hour until ready for dilution;
[0092] A step of removing no more than two vials of reconstituted liposomal anamycin at a time from storage at 37 ℃ ± 4 ℃, carefully inverting each vial once, recovering a bubble-free suspension from the vials while maintaining negative pressure throughout the recovery of the suspension;
[0093] A step of slowly introducing the recovered, foam-free suspension of the reconstituted liposomal anamycin into a pre-warmed non-PVC IV bag of physiological saline prepared as above, and repeating this process for a second vial;
[0094] The step of removing the vial, recovering the suspension, and introducing the suspension into a preheated IV bag is repeated until all vials of reconstituted liposomal anamycin required for the total dose of anamycin are introduced into a non-PVC IV bag, thereby providing an IV bag containing a final reconstituted liposomal anamycin at a concentration of about 0.5 mg / mL; and
[0095] A step of stirring the physiological saline and reconstituted liposomal anamycin in the IV bag by carefully inverting the container several times without generating foam.
[0096] In some embodiments, the free liposomal anamycin lyophilized product comprises anamycin, one or more lipids, and one or more non-ionic surfactants. In some embodiments, the lipids comprise DMPC and DMPG, and the non-ionic surfactant comprises a polysorbate-type surfactant formed from the addition of a carboxylic acid following the ethoxylation of sorbitan. In some embodiments, the non-ionic surfactant comprises polyoxyethylene sorbitan monolaurate. In some embodiments, the free liposomal anamycin lyophilized product comprises 1.8–2.2 wt% anamycin; 3.0–3.4 wt% polysorbate 20; and 94.4–95.2 wt% lipids selected from DMPC and DMPG. In some embodiments, DMPC is 65.3 - 67.3 wt % and DMPG is 27.1 - 29.9 wt %.
[0097] As a treatment method, a method is also provided for a patient requiring this, comprising the injection of an effective dose of reconstituted liposomal anamycin prepared from a lyophilized liposomal anamycin by the above method (wherein the temperature of the liposomal formulation is maintained at 37 ℃ ± 4 ℃ throughout during reconstitution and administration) and used within 24 hours.
[0098] Uses of the reconstituted liposomal anamycin for cancer treatment are also provided, comprising administering an effective dose of the diluted liposomal anamycin prepared as above to a patient requiring this. In some embodiments, the cancer is selected from breast cancer, leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, gastric cancer, Hodgkin and non-Hodgkin lymphoma, ovarian cancer, thyroid cancer, colon cancer, transitional cell bladder cancer, and Wilms tumor.
[0099] Reconstituted liposomal anamycin prepared as described herein is useful for the treatment of certain human cancers, e.g., breast cancer; leukemia, including, e.g., acute myeloid leukemia (AML) and acute lymphoblastic leukemia; gastric cancer; Hodgkin and non-Hodgkin lymphomas; ovarian cancer; thyroid cancer; colon cancer; transitional cell bladder cancer; and Wilms tumor.
[0100] Dose rat and route of administration.
[0101] Generally, reconstituted liposomal formulations are used within 24 hours of reconstitution for the treatment of patients in a condition where treatment would be beneficial. Intravenous administration of the drug is achieved by standard methods and is completed within 110 to 130 minutes, depending on the dosage.
[0102] Liposomal anamycin is used in the treatment of cancer and in the inhibition of tumor growth in mammals, particularly humans. Cancers that can be treated include leukemia and lymphoma. In particular, anamycin can be used in the treatment of leukemias, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphoblastic leukemia (CLL). Liposomal anamycin can be used in the treatment of lymphomas, including Hodgkin and non-Hodgkin lymphomas. The method involves administering an effective amount of the drug composition to a mammal.
[0103] The stage of administration may suitably be parenteral and may be by intravenous, intra-arterial, intramuscular, intralymphatic, intraperitoneal, subcutaneous, intrapleural, or intravertebral injection, or by topical application. In some embodiments, anamycin is administered intravenously. In some embodiments, such administration is a regimen of repeated administration until tumor regression or extinction is achieved and may be used in conjunction with tumor therapy, such as surgery or chemotherapy using different agents. In some embodiments, the administered dose of the composition is approximately 120 to 250 mg / m² for the mammalian subject to which it is administered.2 am.
[0104] The present invention is further explained by the following examples, which should not be interpreted as imposing any limitation on the scope of the invention. On the contrary, it will be clearly understood that reliance may be placed on various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest to those skilled in the art without departing from the subject matter of the invention and / or the appended claims.
[0105] Example 1
[0106] General method
[0107] A. Material
[0108] Free liposomal anamycin lyophilized product was prepared as a powder containing DMPC, DMPG, polysorbate 20, and anamycin.
[0109] Dimyristoyl phosphatidylcholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-[phosphorac-(1-glycerol)] sodium salt (DMPG) were obtained as dry powders from Nippon Fine Chemicals, Inc. (Osaka, Japan).
[0110] Anamycin was synthesized with a slight modification as previously described using a THF solvent compound (>95% pure) (MW=640.39) (Horton, D., Priebe, W. 4-demethoxy-3'-desamino-2'-halo-anthracyclines and pharmaceutical compositions containing same. U.S. Patent No. 4,537,882, 1985).
[0111] Ordinary physiological saline was obtained from Abbott Laboratories (North Chicago, Illinois).
[0112] In the following examples, the reconstitution of pre-liposomal anamycin was performed according to the following method:
[0113] Step 1: Preparation of normal saline syringe and IV bag
[0114] All procedures were performed using sterilization technology in a laminar flow hood or clean room.
[0115] One syringe (45 mL) of physiological saline (0.9% sodium chloride, injection USP) was prepared for each 45 mg vial of liposomal anamycin to be used. These syringes of physiological saline were used for the reconstitution of pre-liposomal anamycin. For example, when the total dose of liposomal anamycin was 360 mg, eight syringes were prepared.
[0116] The syringe was placed in a 37°C oven or IV bag warmer for at least 2-3 hours.
[0117] A non-PVC IV bag was prepared containing an additional volume of saline equivalent to the total volume of saline in the syringe used for the reconstitution of pre-liposomal anamycin. The size of the IV bag was sufficient to hold twice the volume of saline in the syringe. For example, when the total dose of the study drug is 360 mg, eight (8) 45-mg vials of pre-liposomal anamycin are required, each requiring 45 mL of saline or a total of 360 mL of saline. Therefore, a non-PVC IV bag containing 360 mL of saline was also prepared. This was accomplished by removing 640 mL of saline from a standard 1,000 mL non-PVC IV bag of saline. The 1,000 mL IV bag was sufficient to hold twice the volume of saline remaining in the bag, i.e., 2 x 360 mL = 720 mL.
[0118] The prepared saline IV bag was warmed in a commercially available IV bag warmer preheated to approximately 37°C or in an oven heated to 37°C according to the manufacturer's instructions. Before using the IV bag in a subsequent step, it was placed in the bag warmer or oven for approximately 2-3 hours to allow the IV bag to reach a temperature of about 37°C.
[0119] Step 2: Reconstitution of Free Liposomal Anamycin Lyophilized Powder
[0120] Vials of pre-liposomal anamycin lyophilized, each containing 45 mg of anamycin and not including the weight of THF solvent, with a combined weight sufficient to provide the total required dose of the drug, were removed from the freezer and left to stand at room temperature for about 30 minutes to about 2 hours. Any dry cake of pre-liposomal lyophilized anamycin formed was broken up by vigorously shaking the vial.
[0121] The vials were transferred to a laminar flow hood, and air was injected into each vial using an air-filled syringe until the air pressure was equal. One syringe of 45 mL saline solution was removed at a time from a 37 °C oven or an IV bag warmer preheated to 37 °C and used immediately for reconstitution. To minimize possible cooling, the bag warmer or oven was placed inside or right next to the hood where the lyophilized pre-liposomal anamycin was being reconstituted. The saline solution used for reconstitution was 37 °C (± 4 °C) when mixed with the lyophilized drug product in the vials.
[0122] One syringe at a time was removed from the bag warmer or oven immediately before mixing with the pre-liposomal anamycin lyophilized solution. For example, a syringe of 45 mL of normal saline was removed from a 37°C IV bag warmer or oven, and 45 mL of 37°C normal saline was added to the first 45-mg vial of pre-liposomal anamycin lyophilized solution to provide a final anamycin concentration of approximately 1 mg / mL. After addition, normal pressure was achieved using a needle that accurately pierced the septum. The needle was removed, the vial was immediately shaken vigorously by hand for 2 minutes, placed inside a zippered vinyl bag, and then placed back into a 37°C oven or bag warmer.
[0123] Then, in a similar manner, an additional syringe of 45 mL of normal saline was removed from a 37°C IV bag warmer or oven, one at a time, and 45 mL of 37°C normal saline was added to each additional 45-mg vial of pre-liposomal anamycin lyophilized, shaken, and placed in a sealed vinyl bag. Each vial was placed in its own vinyl bag and kept in an oven or bag warmer until all vials required for the total dose of pre-liposomal anamycin were reconstituted.
[0124] When all vials were reconstituted and placed in an oven or bag warmer, two to four vials were removed, shaken for an additional 1–2 minutes, and then placed back in the oven or bag warmer. This was performed until all vials had been shaken a second time. The vials were left to stand at 37°C for 30 minutes to 1 hour before initiating dilution into the final IV bag as described in Step 2 below.
[0125] Particle size analysis was performed on samples of reconstituted anamycin, and it was confirmed that the average particle size was consistently about 8 µm, 50% were distributed in the range of about 5-10 µm, and 90% were distributed in the range of about 2-20 µm.
[0126] Step 3: Dilution of liposomal anamycin into the IV bag
[0127] The dilution of liposomal anamycin was completed within approximately 1 hour of reconstitution. The vial of reconstituted liposomal anamycin, prepared as described in Step 2, was kept at approximately 37°C before being transferred to an IV bag for dilution and was not removed from the 37°C oven until immediately before dilution.
[0128] A vial of reconstituted liposomal anamycin (45 mg in 45 mL of saline, one at a time), prepared as described in Step 2 above and containing a measured amount of physiological saline at approximately 37°C for dilution, was removed from a 37°C oven. The vial was carefully inverted, and the liposomal suspension was recovered via a syringe. If necessary to equalize pressure, the septum was punctured for 1 second, the needle was removed, and the recovery of the drug was continued. The suspension was immediately and slowly transferred (to avoid foaming) into a pre-warmed non-PVC IV bag prepared as in Step 1. Care was taken to prevent any foam from being transferred.
[0129] In a similar manner, additional vials sufficient to provide the required total dose of pre-liposomal anamycin were removed from the oven, one at a time, carefully inverted, and the liposomal anamycin suspension was recovered via syringe and slowly transferred into the contents of a pre-warmed non-PVC IV bag until all vials were immediately transferred to a non-PVC IV bag containing physiological saline for dilution. The physiological saline and liposomal anamycin in the IV bag were mixed by carefully inverting the container several times to prevent the formation of foam. The time was recorded on the IV bag. The final liposomal anamycin concentration was approximately 0.5 mg / mL.
[0130] Throughout this step, the reconstituted liposomal anamycin diluted IV bag was immediately transferred to a preheated IV bag warmer and maintained at approximately 37°C.
[0131] When the IV bag warmer was ready to be moved to the patient infusion room, the plug was removed, the patient was moved within 30 to 60 minutes, and the plug was inserted right near the patient for the infusion. The diluted liposomal anamycin suspension was maintained at approximately 37°C until and during the patient infusion.
[0132] Reconstituted liposomal anamycin diluted with physiological saline was stable for 24 hours when maintained at approximately 37°C, after which the drug was not permitted to be administered to subjects. Only non-PVC and non-DEHP tubing was used for drug administration.
[0133] The time from the start of reconstitution to the completion of the 2-hour infusion was carefully recorded. It was not permitted for more than 24 hours to elapse from the time of reconstitution to the time of completion of the infusion.
[0134] Example 2
[0135] Temperature research
[0136] Appearance tests were performed on each sample. Additional appearance observations were performed immediately after the reconstitution of the sample material at each temperature. Random changes in appearance occurring over the duration of the particle size test were also observed.
[0137] The appearance results obtained before and immediately after the reconstruction of the sample material are presented below, along with the appearance after the particle size test. For all samples, the appearance results before reconstruction were consistent with the target limits. However, the appearance after reconstruction was temperature-dependent. As the sample temperature increased, the likelihood of finely dispersed particles decreased. Clusters of finely dispersed particles were observed at temperatures of 20–25°C, but no evidence of these clusters was observed at temperatures of 28–42°C. Additionally, the table shows that the change in appearance after reconstruction at the end of the particle size test was limited to cases at lower temperatures. These lower-temperature samples tended to disperse the particle clusters present immediately after reconstruction, but not always completely. Unsurprisingly, the appearance of the higher-temperature samples remained consistent, as clusters of finely dispersed particles were not present immediately after reconstruction.
[0138]
[0139] These observations were performed at the time of sample analysis, approximately 1–2 hours after appearance following reconstruction.
[0140] Particle size studies were performed using a laser diffraction particle size analyzer. Single samples were prepared and analyzed at temperatures of 37 (nominal), 20, 23, 25, 28, 30, and 42 °C, respectively. Each step of sample preparation (i.e., incubation temperature, etc.) and analysis (i.e., instrument dispersant temperature, etc.) was performed at the specified temperatures.
[0141] The results obtained from the temperature study of particle size analysis are presented below. Histogram result overlays are shown in Figures 2–4. Overall, the particle size results for samples at 20–25°C differed significantly from the target limits, while the results for samples at 28–42°C were similar. The extremely large particle size results for the 20°C samples suggest that the sample material did not form liposomes upon reconstitution. The results for samples at 23–25°C were significantly smaller than the target limits, implying that liposome formation is in progress. The results for samples at 28–42°C are much more stable and similar to the target limits. This suggests that liposomes are fully formed and are quite stable within this temperature range. However, it should be noted that the results for the 28°C samples do not fall within the target limits. This highlights that while particle size transitions occur in the temperature range of 25–28°C, liposomes cannot be fully formed until a temperature of approximately 30°C is reached. Finally, when looking at the results for samples from 28–42°C, it should be noted that Dv90 results increase as the temperature increases.
[0142]
[0143] *Nominal
[0144] Note: Full precision values are provided for the three significant figures for improved data interpretation.
[0145] Both the appearance and particle size results show that temperature affects the particle size distribution of the reconstituted drug product liposomes. Reconstitution at temperatures of 20–25°C leaves the particle clusters in a finely dispersed state, while the particle size results for these temperatures differ significantly. The appearance and particle size results for temperatures of 28–42°C are much more stable, suggesting a transition temperature range of approximately 25–28°C. All of this data suggests that the drug product is reconstituted and maintained at temperatures of approximately 30–42°C.
[0146] Although the present invention has been described with reference to specific embodiments and examples, those skilled in the art understand that various modifications may be made to the present invention without departing from the subject and scope of the invention.
[0147] All references cited herein, including patents, patent applications, and publications, are incorporated herein by reference in their entirety, regardless of whether they were previously specifically included.
[0148] The various features and embodiments of the present invention mentioned in the individual parts above shall, where appropriate, be applied to other parts. Consequently, a feature specified in one part may, where appropriate, be combined with a feature specified in another part.
[0149] The foregoing description of certain specific embodiments provides sufficient information to enable others to easily modify or adapt such specific embodiments for various applications by applying current knowledge without departing from the general concept, and therefore such modifications and adaptations should be understood and intended to be understood within the meaning and scope of the equivalents of the disclosed embodiments. It will be understood that the language or terms used herein are for descriptive purposes only and not for limiting purposes. In the drawings and specification, exemplary embodiments are disclosed and specific terms may be used, but unless otherwise stated, they are used only in a general and descriptive sense and not for the purpose of limiting the claims. Furthermore, those skilled in the art will understand that specific steps of the method discussed herein may be arranged in an alternative order or that the steps may be combined. Therefore, it is intended that the appended claims are not limited to the specific embodiments disclosed herein. Those skilled in the art will be able to understand or identify many equivalents to the embodiments of the invention described herein using only routine experimentation. Such equivalents are encompassed by the following claims.
Claims
Claim 1 A method for reconstitutement of anamycin comprising the following steps: adding physiological saline at 37 ℃ ± 4 ℃ to one or more containers of lyophilized liposomal anamycin to form suspended liposomal anamycin with a concentration of 0.5-1.5 mg / mL; maintaining the one or more containers at 37 ℃ ± 4 ℃; diluting the suspended liposomal anamycin with physiological saline at 37 ℃ ± 4 ℃ to provide diluted liposomal anamycin with a concentration of 0.3-0.7 mg / mL in physiological saline; and maintaining the one or more containers of suspended liposomal anamycin and the diluted liposomal anamycin at 37 ℃ ± 4 ℃ during and after dilution. Claim 2 In claim 1, the suspended liposomal anamycin is a reconstitution method having a concentration of 1 mg / mL. Claim 3 In claim 1, the total weight of the diluted liposomal anamycin is a reconstitution method equivalent to the required effective dose. Claim 4 A reconstitution method according to claim 1, wherein the suspended liposomal anamycin is diluted by adding it into a physiological saline-containing IV bag at 37 ℃ ± 4 ℃. Claim 5 A reconstitution method according to claim 1, wherein the temperature of the suspended liposomal anamycin is maintained at a temperature of 37 ℃ ± 4 ℃ before, during, and after dilution. Claim 6 In claim 1, the diluted liposomal anamycin is a reconstitution method with a concentration of 0.5 mg / mL. Claim 7 A reconstitution method according to claim 1, wherein the suspension of liposomal anamycin is maintained at 37 ℃ ± 1 ℃ and the diluted liposomal anamycin is maintained at 37 ℃ ± 1 ℃. Claim 8 A method for preparing an effective dose of a reconstituted liposomal formulation of anamycin, comprising the following steps: heating a syringe and a non-PVC IV bag, each containing 0.9% aqueous injection of physiological saline USP sodium chloride, in an oven or bag warmer at 37°C ± 4°C for at least 3 hours, wherein the volume of physiological saline (in mL) in the syringe is equivalent to the weight (in mg) of the pre-liposomal lyophilized anamycin to be reconstituted, the volume of physiological saline in the IV bag is equivalent to the total amount of physiological saline in all syringes, and the volume of the IV bag has a capacity sufficient to contain the total volume of physiological saline and liposomal anamycin for diluting the total dose of liposomal anamycin; removing a sufficient number of pre-liposomal anamycin lyophilized-containing vials from a freezer to provide the desired total dose of anamycin, and placing the vials at room temperature for 30 Steps for standing for minutes to 2 hours; vigorously shaking each vial of pre-liposomal lyophilized anamycin to break up any dry cake; injecting air into each vial from an air-filled syringe until the pressure within each vial becomes equal; adding a fixed volume of 37°C ± 4°C physiological saline from a syringe maintained at 37°C ± 4°C in an oven to the vial containing pre-liposomal lyophilized anamycin in a weight-equivalent vial, and maintaining negative pressure throughout the addition of physiological saline; immediately shaking the vial vigorously back and forth by hand for 15 seconds, and then placing the vial in a resealable polyethylene storage bag; repeating the steps of adding physiological saline, shaking the vial, and placing the vial in the storage bag until all vials required for the total dose of anamycin are similarly prepared; all Step of shaking the vials, 2-4 at a time for 1-2 minutes, and then a second time;A step of storing all vials of reconstituted liposomal anamycin at 37 °C ± 4 °C for 30 minutes to 1 hour until ready for dilution; a step of removing no more than two vials of reconstituted liposomal anamycin at a time from storage at 37 °C ± 4 °C, carefully inverting each vial once, recovering the foam-free suspension from the vials while maintaining negative pressure throughout the recovery of the suspension; a step of slowly introducing the recovered foam-free suspension of reconstituted liposomal anamycin into a non-PVC IV bag of physiological saline preheated at 37 °C ± 4 °C, prepared as above, and repeating the step for a second vial; a step of removing vials, recovering the suspension, and introducing the suspension into a preheated IV bag, repeating the step of removing vials, recovering the suspension, and introducing the suspension into a preheated IV bag until all vials of reconstituted liposomal anamycin required for the total dose of anamycin are introduced into the non-PVC IV bag, thereby concentrating A step of providing an IV bag containing 0.5 mg / mL of final reconstituted liposomal anamycin; and a step of stirring the physiological saline and reconstituted liposomal anamycin in the IV bag by carefully inverting the container several times without generating foam. Claim 9 A method of manufacture according to claim 8, wherein the syringe and non-PVC IV bag are heated in an oven or bag warmer at a temperature of 37 ℃ ± 4 ℃ for 2-3 hours. Claim 10 A method of manufacture according to claim 8, wherein the IV bag comprises an IV drip line, and the IV drip line comprises a heated protective sleeve for maintaining the diluted liposomal anamycin at a temperature of 37 ℃ ± 4 ℃ until and during infusion to the patient. Claim 11 In claim 10, a manufacturing method in which the heated protective sleeve is insulated. Claim 12 In claim 8, the manufacturing method is to unplug the IV bag warmer while it is being moved to the patient infusion room, and then immediately plug it back in at the patient infusion room. Claim 13 A pharmaceutical composition for use in the treatment of cancer, comprising an effective dose of diluted liposomal anamycin prepared as in any one of claims 1 to 12. Claim 14 A pharmaceutical composition according to claim 13, wherein the liposomal anamycin is prepared such that the preheated physiological saline solution has a temperature of 37 ℃ ± 4 ℃, or the temperature of the suspended liposomal anamycin is maintained at a temperature of 37 ℃ ± 4 ℃ before, during, and after dilution, or the suspension of the liposomal anamycin is maintained at 37 ℃ ± 1 ℃ and the diluted liposomal anamycin is maintained at 37 ℃ ± 1 ℃. Claim 15 A pharmaceutical composition according to claim 13, wherein the cancer is present in a human patient and the cancer is selected from leukemia and lymphoma. Claim 16 A pharmaceutical composition according to claim 13, wherein the cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma.
Citation Information
Patent Citations
Submicron liposome suspensions obtained from preliposome lyophilizates
US7238366B1
